Daraxonrasib in First-Line Pancreatic Cancer: 60.7% Response With Chemotherapy
Updated RMC-GI-102 data at ENA 2026 show Rasonque (daraxonrasib) plus gemcitabine and nab-paclitaxel achieved a 60.7% response rate, 12.8-month PFS and 76.6% one-year survival in untreated metastatic pancreatic cancer.
